SUNPHARMAPharmaceuticals
Sun Pharmaceutical Industries Ltd — PE Ratio & Valuation Analysis
₹1757.20
+0.66%
Current P/E37.57xPrice to earnings
Industry P/E31.77xSector average
4Y Avg P/E48.6x22.7% below avg
⚠️
18.3% Premium to Industry
SUNPHARMA P/E 37.57x vs sector avg 31.77x
📊
Historical PE Ratio
| Year | EPS (₹) | Year-end Price | PE Ratio |
|---|---|---|---|
| 2025 | ₹45.60 | ₹1720 | 37.7x |
| 2024 | ₹39.90 | ₹1886 | 47.3x |
| 2023 | ₹35.30 | ₹1259 | 35.7x |
| 2022 | ₹13.60 | ₹1001 | 73.6x |
PE = Year-end closing price ÷ Diluted EPS. Source: NSE/BSE filings.
💡
Understanding Sun Pharmaceutical Industries Ltd Valuation
Sun Pharmaceutical Industries Ltd (SUNPHARMA) currently trades at 37.57x earnings. The Pharmaceuticals sector average PE is 31.77x. SUNPHARMA commands a premium, reflecting high growth expectations. Historically, SUNPHARMA has traded at an average PE of 48.6x — it is currently below that level. Always evaluate PE alongside earnings growth (PEG ratio), return on equity, debt levels and business quality. A lower PE isn't always better. Educational data only — not investment advice.
ROE
16.86%
Dividend Yield
0.89%
More on Sun Pharmaceutical Industries Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.